版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)
文檔簡介
EB病毒DNA與鼻咽癌治療預(yù)后之有關(guān)聯(lián)性
TherelationshipbetweenEBVDNAandprognosisinnasopharyngealcarcinoma蘇彥燁第1頁OutlineIntroductionofnasopharynxIntroductionofnasopharyngealcarcinoma(NPC)RelatedarticlesofEBVDNAandNPCprognosis-EBVDNAlevelandNPCrecurrence-EBVDNAlevelanddistantmetastasis-EBVDNAlevelandsurvival-EBVDNAlevelandtreatmentresponse第2頁Thenasopharynx(nasalpartofthepharynx)istheuppermostpartofthepharynxItextendsfromthebaseoftheskulltotheuppersurfaceofthesoftpalateNasopharynx第3頁FossaofRosenmullerNasopharynx第4頁ExaminationofNasopharynx第5頁第6頁Nasopharyngoscope第7頁FossaofRosenmuller第8頁NasopharyngealCarcinoma(NPC)Epidemiology---CommoninsouthernregionsofChina,particularlyinGuangdong,Fujian,Hong-kongandTaiwan150casesper100,000peopleinGuangdong,7.7casesper100,000peopleinTaiwan,and0.1~1.7per100,000peopleinUSANPCisseenprimarilyinmiddle-aged(45~55y/o)personsinAsia,ahighproportionofAfricancasesappearinchildren第9頁Etiology---Cause??NotclearEBvirus-relatedtoundifferentiatedtypeGene-(HLA-A2,Aw19,BSin2,B17,BW16)Diet(saltedvegetables,fishandmeat-dimethylnitrosamines)Environmentsmoking,nickelexposure,formaldehyde(甲醛)NasopharyngealCarcinoma(NPC)第10頁NPCNormal第11頁SymptomsandSignsNeckmassEarfullnessandhearingimpairment(middleeareffusion)BloodtingledsputumNasalobstructionHeadacheDiplopia第12頁DiagnosisandTreatmentBiopsy!!!TreatmentRadiotherapy+/-chemotherapyOperation(salvage)第13頁RelatedArticlesof
EBVDNAandNPCprognosis第14頁EBVDNAlevelandNPCrecurrence第15頁EBVDNAlevelandNPCrecurrencePlasma/serumcell-freeEBVDNAmaybeavaluabletoolforthemonitorofNPCpatientsfortheearlydetectionoftumorrecurrenceLoYM.etal.CancerRes.1999CirculatingEBVDNAhasbeenfoundnotonlytocorrelatewithdiseasestaging,butalsotoprovideusefulinformationforthemonitoringfortumorrecurrenceLoYM.etal.BiomedPharmacother.2023.ReviewThefailureofcompleteandrapideliminationofEBVDNAfromthecirculationpredictsdiseaserecurrenceToEW.etal.ClinCancerRes.2023第16頁ThisstudyprovideconvincingevidencefortheuseofplasmaEBVDNAmeasurementsfortheearlydiagnosisandstagingofNPCawellasformonitoringrecurrenceandmetastasisofthistumorShaoJY.etal.Cancer.2023TheusefulnessofEBVDNAasausefultoolinmonitoringNPCbyitsabilitytodetectearlyrecurrenceandexcellentcorrelationwithtreatmentresponseChanSLetal.BMCCancer.2023TheplasmaEBVDNAassaycorrectlypredictedallNPCrecurrences,andPEThadhighcapacitytolocalizepotentiallesionsitesWangWYetal.Cancer.2023EBVDNAlevelandNPCrecurrence第17頁Therisksofloco-regionalfailurewerenotsignificantlydifferentbetweenpatientswithhighandthosewithlowEBVDNAlevelsLeungSF.etal.Cancer.2023PlasmaEBVDNAloadmeasurementappearstobeusefulinalowtumorriskarea(westernEurope).However,developmentoflocalrecurrencesmaynotalwayscoincidewithraisedlevelofEBVDNAKalpoeJS.etal.JClinPathol.2023EBVDNAlevelandNPCrecurrence第18頁Conclusion---NPCrecurrencewashighlyrelatedtoEBVDNAlevel,butnotalwayscoincidedWithanasymptomaticriseintheplasmaEBVDNAlevel,tumorrecurrenceshouldbeconsideredEBVDNAlevelandNPCrecurrence第19頁EBVDNAlevelanddistantmetastasis第20頁EBVDNAlevelanddistantmetastasisPatientswithdistantfailurehadsignificantlyhigherpre-therapyEBVDNAlevelsthanthosewithoutfailureLeungSF.etal.Cancer2023KaplanMeierplotoffreedomfromdistantfailureforpatientsubgroupswithhighversuslowpretherapyEpsteinBarrvirus(EBV)DNAlevels第21頁ThetimetothefirstdetectionofcirculatingEBVDNAwassignificantlyshorteramongpatientswithdistantmetastasis.MonitoringplasmaEBVDNAlevelsurpassedtraditionalmethodsfortheearlydetectionofdistantfailureinpatientswithNPCHongRL.etal.Cancer.2023TheuseofplasmaEBVDNAmeasurementsfortheearlydiagnosisandstagingofNPCawellasformonitoringrecurrenceandmetastasisofthistumorShaoJY.etal.Cancer2023EBVDNAlevelanddistantmetastasis第22頁Conclusion---EBVDNAlevelwashighlyrelatedtodistantmetastasisClosemonitoringEBVDNAlevelcouldearlydetectdistantfailureinNPCpatientsEBVDNAlevelanddistantmetastasis第23頁EBVDNAlevelandsurvival第24頁Levelsofpost-treatmentplasmaEBVDNAinpatientswithNPCappeartostronglypredictprogression-freeandoverallsurvivalandtoaccuratelyreflectthepost-treatmentresidualtumorloadChanAT.etal.JNatlCancerinst.2023Pre-therapycirculatingEBVDNAloadisanindependentprognosticfactorforoverallsurvivalinNPCLeungSF.etal.JClinOncol.2023EBVDNAlevelandsurvival第25頁SurvivalprobabilitiesofpatientgroupsaccordingtoEpstein-Barrvirus(EBV)DNAlevels.LowDNAdenoteslowEBVDNAlevelsoflessthan4000copies/ml,andhighDNAdenoteshighEBVDNAlevelsof4000copies/mlLeungSF.etal.JClinOncol.2023第26頁EBVDNAstatusremainsastrongpredictorforoverallsurvivalinNPCKennethWY.etal.ClinCancerRes.2023Metastatic/recurrentNPCpatientswithlowpre-treatmentplasmaEBVDNAlevelandundetectablepost-treatmentplasmaEBVDNAshowedafavorableprognosisandsurvivalAnX.etal.Cancer.2023EBVDNAlevelandsurvival第27頁The5-yearoverallsurvivalrateinlowpre-treatmentplasmaEBVDNAlevelandundetectablepost-treatmentplasmaEBVDNAsubgroupwas50.6%.However,nopatientsintheother3subgroupssurvived5yearsAnX.etal.Cancer.2023第28頁Conclusion---EBVDNAlevelwashighlyrelatedtosurvivalrateLowerpre-treatmentplasmaEBVDNAlevelandundetectablepost-treatmentplasmaEBVDNAshowedthebestprognosisEBVDNAlevelandsurvival第29頁EBVDNAlevelandtreatmentresponse第30頁EBVDNAlevelandtreatmentresponseRapidclearanceofplasmaEpstein-BarrvirusDNAaftersurgicaltreatmentofnasopharyngealcarcinomaToEW.etal.ClinCanerRes.2023TheinvivoeliminationofEBVDNAisveryrapidaftersurgicalresectionofNPCThefailureofcompleteandrapideliminationofEBVDNAfromthecirculationpredictsdiseaserecurrence第31頁PlasmaEBVDNAclearancerateasanovelprognosticmarkerformetastatic/recurrentnasopharyngealcarcinomaWangWY.etal.ClinCancerRes.2023Patientswithashortt1/2ofplasmaEBVDNAclearancehavesignificantlyhighercompleteresponserateandoverallsurvivalthanthosewithlongt1/2TheplasmaEBVDNAconcentrationshavenosignificanteffectsonoutcomepredictionEBVDNAlevelandtreatmentresponse第32頁第33頁第34頁TheplasmaEBVDNAconcentrationshavenosignificanteffectsonoutcomepredictionThet1/2ofplasmaEBVDNAclearanceshowssignifi
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024年涂料產(chǎn)品質(zhì)量承諾保證書
- 臨時性勞務(wù)用工合同樣本
- 住家保姆勞務(wù)合同范本
- 店面出租合同樣式
- 業(yè)務(wù)員提成協(xié)議書范本2024年
- 2024以土地入股建廠合同
- 貴州省七年級上學(xué)期語文期中試卷7套【附答案】
- 工程總承包合同書模板示例
- 企業(yè)合作項目協(xié)議
- 借款合同范例解析
- 實驗動物學(xué)完整版本
- 知識點默寫單-2024-2025學(xué)年統(tǒng)編版道德與法治九年級上冊
- 科大訊飛財務(wù)報表分析報告
- 2024-秋季新版人教版三年級上冊英語單詞
- Java開發(fā)工程師招聘筆試題及解答(某大型央企)2024年
- 2024年新人教版道德與法治一年級上冊 12 玩也有學(xué)問 教學(xué)課件
- 北師大版八年級上冊數(shù)學(xué)期中考試試卷帶答案
- 地形圖測繪報告
- 《數(shù)學(xué)廣角-集合》說課稿
- 2024無障礙環(huán)境建設(shè)法知識競賽題庫及答案
- 2024-2025學(xué)年部編版語文八年級上冊 期中綜合測試卷(四)
評論
0/150
提交評論